Tags

Type your tag names separated by a space and hit enter

Impact of Vitamin D Deficiency on COVID-19-A Prospective Analysis from the CovILD Registry.
Nutrients. 2020 Sep 11; 12(9)N

Abstract

The novel Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a global health concern. Vitamin D (VITD) deficiency has been suggested to alter SARS-CoV-2 susceptibility and the course of disease. Thus, we aimed to investigate associations of VITD status to disease presentation within the CovILD registry. This prospective, multicenter, observational study on long-term sequelae includes patients with COVID-19 after hospitalization or outpatients with persistent symptoms. Eight weeks after PCR confirmed diagnosis, a detailed questionnaire, a clinical examination, and laboratory testing, including VITD status, were evaluated. Furthermore, available laboratory specimens close to hospital admission were used to retrospectively analyze 25-hydroxyvitamin D levels at disease onset. A total of 109 patients were included in the analysis (60% males, 40% females), aged 58 ± 14 years. Eight weeks after the onset of COVID-19, a high proportion of patients presented with impaired VITD metabolism and elevated parathyroid hormone (PTH) levels. PTH concentrations were increased in patients who needed intensive care unit (ICU) treatment, while VITD levels were not significantly different between disease severity groups. Low VITD levels at disease onset or at eight-week follow-up were not related to persistent symptom burden, lung function impairment, ongoing inflammation, or more severe CT abnormalities. VITD deficiency is frequent among COVID-19 patients but not associated with disease outcomes. However, individuals with severe disease display a disturbed parathyroid-vitamin-D axis within their recovery phase. The proposed significance of VITD supplementation in the clinical management of COVID-19 remains elusive.

Authors+Show Affiliations

Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Central Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Innsbruck, 6020 Innsbruck, Austria.Central Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Innsbruck, 6020 Innsbruck, Austria. Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria. MLL Munich Leukemia Laboratory, Klinikum Groβhadern, 81377 Munich, Germany.Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Radiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria. Christian Doppler Laboratory for Iron Metabolism and Anemia Research, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study

Language

eng

PubMed ID

32932831

Citation

Pizzini, Alex, et al. "Impact of Vitamin D Deficiency On COVID-19-A Prospective Analysis From the CovILD Registry." Nutrients, vol. 12, no. 9, 2020.
Pizzini A, Aichner M, Sahanic S, et al. Impact of Vitamin D Deficiency on COVID-19-A Prospective Analysis from the CovILD Registry. Nutrients. 2020;12(9).
Pizzini, A., Aichner, M., Sahanic, S., Böhm, A., Egger, A., Hoermann, G., Kurz, K., Widmann, G., Bellmann-Weiler, R., Weiss, G., Tancevski, I., Sonnweber, T., & Löffler-Ragg, J. (2020). Impact of Vitamin D Deficiency on COVID-19-A Prospective Analysis from the CovILD Registry. Nutrients, 12(9). https://doi.org/10.3390/nu12092775
Pizzini A, et al. Impact of Vitamin D Deficiency On COVID-19-A Prospective Analysis From the CovILD Registry. Nutrients. 2020 Sep 11;12(9) PubMed PMID: 32932831.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of Vitamin D Deficiency on COVID-19-A Prospective Analysis from the CovILD Registry. AU - Pizzini,Alex, AU - Aichner,Magdalena, AU - Sahanic,Sabina, AU - Böhm,Anna, AU - Egger,Alexander, AU - Hoermann,Gregor, AU - Kurz,Katharina, AU - Widmann,Gerlig, AU - Bellmann-Weiler,Rosa, AU - Weiss,Günter, AU - Tancevski,Ivan, AU - Sonnweber,Thomas, AU - Löffler-Ragg,Judith, Y1 - 2020/09/11/ PY - 2020/08/10/received PY - 2020/09/07/revised PY - 2020/09/09/accepted PY - 2020/9/16/entrez PY - 2020/9/17/pubmed PY - 2020/9/25/medline KW - COVID-19 KW - PTH KW - SARS-CoV-2 KW - VITD KW - parathyroid hormone KW - vitamin D JF - Nutrients JO - Nutrients VL - 12 IS - 9 N2 - The novel Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a global health concern. Vitamin D (VITD) deficiency has been suggested to alter SARS-CoV-2 susceptibility and the course of disease. Thus, we aimed to investigate associations of VITD status to disease presentation within the CovILD registry. This prospective, multicenter, observational study on long-term sequelae includes patients with COVID-19 after hospitalization or outpatients with persistent symptoms. Eight weeks after PCR confirmed diagnosis, a detailed questionnaire, a clinical examination, and laboratory testing, including VITD status, were evaluated. Furthermore, available laboratory specimens close to hospital admission were used to retrospectively analyze 25-hydroxyvitamin D levels at disease onset. A total of 109 patients were included in the analysis (60% males, 40% females), aged 58 ± 14 years. Eight weeks after the onset of COVID-19, a high proportion of patients presented with impaired VITD metabolism and elevated parathyroid hormone (PTH) levels. PTH concentrations were increased in patients who needed intensive care unit (ICU) treatment, while VITD levels were not significantly different between disease severity groups. Low VITD levels at disease onset or at eight-week follow-up were not related to persistent symptom burden, lung function impairment, ongoing inflammation, or more severe CT abnormalities. VITD deficiency is frequent among COVID-19 patients but not associated with disease outcomes. However, individuals with severe disease display a disturbed parathyroid-vitamin-D axis within their recovery phase. The proposed significance of VITD supplementation in the clinical management of COVID-19 remains elusive. SN - 2072-6643 UR - https://www.unboundmedicine.com/medline/citation/32932831/Impact_of_Vitamin_D_Deficiency_on_COVID_19_A_Prospective_Analysis_from_the_CovILD_Registry_ L2 - https://www.mdpi.com/resolver?pii=nu12092775 DB - PRIME DP - Unbound Medicine ER -